Study of immune activity after CAR-T therapy for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with diffuse large B-cell lymphoma
- Your doctor has decided to treat you with CAR-T cell therapy (anti-CD19 CAR-T cells)
- You are 18 years or older
- You are willing and able to give your consent to take part in this study
- You must be covered by a health insurance or social security plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
This trial tests a new type of CAR-T therapy designed to target and kill CD20-positive cancer cells in people with blood cancers like B-cell lymphoma or lymphocytic leukemia. It is an early study to see if this approach is safe and works.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a new treatment using your own immune cells (called CART cells) that are engineered to find and destroy cancer cells in certain types of B-cell blood cancers. It might help if standard treatments have stopped working.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.